Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo submitted an NDA Nov. 27 for a fixed-dose combination of its angiotensin receptor blocker Benicar (olmesartan) and the calcium channel blocker amlodipine (currently marketed by Pfizer as Norvasc). The Japanese drug maker told "The Pink Sheet" DAILY it is seeking a standard review for treatment of hypertension